As we move toward the most significant "patent cliff" in oncology history, the Keytruda Market economic outlook for 2028 is becoming the primary focus for global healthcare payers and hospital administrators. Pembrolizumab, which currently accounts for nearly 25% of all cancer medicine expenditures in high-income countries, is projected to see a revenue reduction of over 60% within the...